Economic evaluation of human papilloma virus vaccination in the European Union: A critical review

Internal and Emergency Medicine

Volumn 6, Issue 2, 2011, Pages 163-174

  Koleva, Daniela ^a   de Compadri, Paola ^a   Padula, Anna ^a   Garattini, Livio ^a  

^a CESAV   (Italy)

Author keywords

Economic evaluation; European Union; HPV vaccine

Indexed keywords

WART VIRUS VACCINE;

COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; EUROPEAN UNION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; PAPILLOMAVIRUS INFECTION; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; REVIEW;

COST-BENEFIT ANALYSIS; DECISION MAKING; EUROPEAN UNION; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PUBLIC HEALTH; QUALITY-ADJUSTED LIFE YEARS;

EID: 79953026657     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0529-3     Document Type: Review

References (56)

1. Bosch FX, Lorincz A, Muñoz N et al (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244-265.
2. Pagliusi SR, Aguado MT (2004) Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23: 569-578.
3. Myers E, Huh WK, Wright JD et al (2008) The current and the future role of screening in the era of HPV vaccination. Gynecol Oncol 109(2 Suppl): S31-S39.
4. WHO (2008) Preparing for the introduction of HPV Vaccine in the WHO European Region: strategy paper. Vaccine-Preventable Diseases and Immunization Programme. World Health Organization, Copenhagen.
5. Anttila A, von Karsa L, Aasmaa A et al (2009) Cervical cancer screening policies and coverage in Europe. Eur J Cancer 45: 2649-2658.
6. Bosch FX, Castellsagué X, de Sanjosé S (2008) HPV and cervical cancer: screening or vaccination? Br J Cancer 98: 15-21.
7. Kim S-Y, Goldie SJ (2008) Cost-effectiveness analyses of vaccination programmes, a focused review of modelling approaches. Pharmacoeconomics 26(3): 191-215.
8. Marra F, Cloutier K, Oteng B et al (2009) Effectiveness and cost effectiveness of human papillomavirus vaccine. A systematic review. Pharmacoeconomics 27: 127-147.
9. Cuschieri K (2009) Should boys receive the human papillomavirus vaccine? No. BMJ 339: b4921.
10. Techakehakij W, Feldman RD (2008) Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 28: 6258-6265.
11. Ortega-Sanchez IR, Lee GM, Jacobs RJ et al (2008) Projected cost-effectiveness of new vaccines for adolescents in the United States. Pediatrics 121(Suppl 1): 563-578.
12. Newal AT, Beutels P, Wood JG et al (2007) Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 7: 289-296.
13. Schiffman M, Castle PE, Jeronimo J et al (2007) Human papillomavirus and cervical cancer. Lancet 370: 890-907.
14. Bonati M, Garattini S (2009) Controlling cervical cancer. Pharmacoeconomics 27(2): 91-93.
15. Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928-1943.
16. La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W (2010) HPV vaccine eficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 25: 8352-8358.
17. De Pouvourville G, Ulmann P, Nixon J et al (2005) The diffusion of health economics knowledge in Europe. The EURONHEED (European Network of Health Economic Evaluation Databases) Project. Pharmacoeconomics 23(2): 113-120.
18. Usher C, Tilson L, Olsen J et al (2008) Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 26(44): 5654-5661.
19. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP (2006) Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling. Vaccine 24(Suppl 3): S155-S163.
20. ® in Italy. Vaccine 28: 3379-3384.
21. De Kok IM, van Ballegooijen M, Habbema JDF (2009) Cost-effectiveness analysis of human papillomavirus vaccination in The Netherlands. J Natl Cancer Inst 101(15): 1083-1092.
22. Zechmeister I, de Blasio BF, Garnett G et al (2009) Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 27(37): 5133-5141.
23. Rogoza RM, Westra TA, Ferko N et al (2009) Cost-effectiveness analysis of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in The Netherlands. Vaccine 27(35): 4776-4783.
24. Thiry N, De Laet C, Hulstaert F et al (2009) Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 25(2): 161-170.
25. Annemans L, Rémy V, Oyee J et al (2009) Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 27(3): 231-245.
26. Mennini FS, Giorgi Rossi P, Palazzo F et al (2009) Health and economic impact associated with a quadrivalent HPV vaccine in Italy. GynecolOncol 112(2): 370-376.
27. Coupé VMH, van Ginkel J, de Melker HE et al (2009) HPV vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer 124(4): 970-978.
28. Jit M, Choi YH, Edmunds WJ (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: 769. doi: 10. 11367bmj. a769.
29. Dasbach EJ, Insinga RP, Elbasha EH (2008) The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115(8): 947-956.
30. Bergeron C, Largeron N, McAllister R et al (2008) Cost-effectiveness analysis of the introduction of a quadrivalent human papilloma vaccine in France. Int J Technol Assess Health Care 24(1): 10-19.
31. Boot HJ, Wallenburg I, de Melker HE et al (2007) Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 25(33): 6245-6256.
32. Kulasingam SL, Benard S, Barnabas RV et al (2008) Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 6(4): 4-15.
33. Hillemans P, Petry KU, Largeron N et al (2009) Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health 17: 77-86.
34. Olsen J, Jepsen MR (2010) Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 26(2): 183-191.
35. Villa LL, Perez G, Kjaer SK et al (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915-1927.
36. Paavonen J, Naud P, Salmeròn J et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
37. Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4-5 years of a bivalent L1 virus like particle vaccine against human papillomavirus 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247-1255.
38. Villa LL, Costa RLR, Petta CA et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1-like-particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459-1466.
39. Harper DM, Franco EL, Wheeler C et al (2004) Efficacy of bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-1765.
40. Villa LL, Costa RLR, Petta CA et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278.
41. Stoykova B, Dowie R (2007) HPV testing matters-findings from a time trade-off survey in England. In: IHEA 2007 6th World Congress: explorations in health economics paper. Available at SSRN http://ssrn. com/abstract=945729.
42. Elbasha EH, Dasbach EJ, Insinga RP (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13: 28-41.
43. Myers ER, Green S, Lipkus I (2004) Patient preferences for health states related to HPV infection: visual analogue scales vs. time trade-off elicitation. In: Proceedings of the 21st international papillomavirus conference. Mexico City, Mexico, 20-26 February.
44. Gold M, Franks P, McCoy KI et al (1998) Towards consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 36: 778-792.
45. Woodman CBJ, Collins SI, Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7: 11-22.
46. Wolstenholme JL, Whynes DK (1998) Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 34(12): 1889-1893.
47. Oostenbrink JB, Bouwmans CA, Koopmanschap MA et al (2004) Richtlijnen voor Kostenschattingen in de Gesondheidszorg Guideline for costinng research, methods and standardized prices for economic evaluations in health care. Health Care Insurance Board, Diemen (Netherlands).
48. Cleemput I, van Wilder P, Vrijens F et al (2008) Guidelines for pharmaco-economic evaluations in Belgium. Health Technology Assessment (HTA). In: F. K. v. d. G. (KCE) (ed) KCE reports. Belgian Health Care Knowledge Centre (KCE), Brussels.
49. National Institute for Health and Clinical Excellence (2004) Guide to the methods of technology appraisal (reference N0515). http://www. nice. org. uk/niceMedia/pdf/TAP_Methods. pdf.
50. Haug CJ (2008) Human papillomavirus vaccination-reasons for caution. N Engl J Med 359(8): 861-862.
51. Loos AH, Bray F, McCarron P et al (2004) Sheep and goats: separating cervix and corpus uteri from imprecisely coded uterine cancer deaths, for studies of geographical and temporal variations in mortality. Eur J Cancer 40: 2794-2803.
52. Knies S, Evers SMAA, Candel MJJM et al (2009) Utilities of the EQ-5D. Transferable or not? Pharmacoeconomics 27(9): 767-779.
53. Korfage IJ, Essink-Bot ML, Mols F et al (2009) Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys 73(5): 1501-1509.
54. Whynes DK, Woolley C, Philips Z, for the TOMBOLA Group (2008) Management of low-grade cervical abnormalities detected at screening: which method do women prefer? Cytopathology 19: 355-362.
55. Bell CM, Urbach DR, Ray JG et al (2006) Bias in published cost effectiveness studies: systematic review. BMJ 332: 699-703.
56. Puig-Junoy J, Lopez-Valcarcel BG (2009) Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained. Prev Med 48: 444-448.